Quick Answer
KESTRA MEDICAL TECHNOLOGIES, LTD. reported Diluted EPS of $5.13 per share (loss) for fiscal year 2025.
KESTRA MEDICAL TECHNOLOGIES, LTD. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.13 | -1.2% |
| 2024 | -$5.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | -$0.61 | +51.2% | +4.7% |
| October 31, 2025 | -$0.64 | +46.2% | -28.0% |
| July 31, 2025 | -$0.50 | +55.4% | +60.0% |
| January 31, 2025 | -$1.25 | — | -5.0% |
| October 31, 2024 | -$1.19 | — | -6.2% |
| July 31, 2024 | -$1.12 | — | — |
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed a decrease of -1.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, KESTRA MEDICAL TECHNOLOGIES, LTD.’s diluted eps has declined by 1.2% (from $5.07 per share (loss) to $5.13 per share (loss)).
- The most recent figure is from KESTRA MEDICAL TECHNOLOGIES, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: